clinical trial · NCT03932201
Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A
Bayer·—·active not recruiting·n = 371
Hemophilia ADamoctocog alfa pegol (Jivi, Bay94-9027)
brief summary
The aim of the HEM-POWR study is to understand better how Damoctocog alfa pegol (Jivi) is used to treat people with Hemophilia A in day-to-day life, how well the treatment is tolerated and how satisfied patients and physicians are with the treatment.
started
Oct 21, 2019
primary completion
Dec 31, 2026
completion
Mar 31, 2027
last updated
Jul 1, 2026
official title
Observational Study Evaluating Effectiveness and Safety of Real-World Treatment With Damoctocog Alfa Pegol in Previously Treated Patients With Hemophilia A
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol